Pamplona, September 15, 2026. 3PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
Ponchi joins 3PBIOVIAN with more than 20 years of experience across both the innovator and service-provider sides of the biopharmaceutical industry. Having worked in leading pharmaceutical companies and world-class CDMOs, most recently at FUJIFILM Biotechnologies, she brings a unique understanding of the strategic, technical, and commercial challenges faced by biopharma companies, together with deep insight into how development and manufacturing partners can help accelerate the path from innovation to patients.
Her appointment reflects the scale of 3PBIOVIAN’s growth ambitions and its commitment to building a strong, globally connected commercial organization. With a proven track record at a leading global CDMO, Ponchi brings extensive experience in building strategic partnerships and engaging with biopharmaceutical innovators at the highest level. Her leadership will further strengthen 3PBIOVIAN’s ability to develop long-term customer relationships and support increasingly complex development and manufacturing programs.
“As the market continues to evolve, customers are increasingly looking for partners that combine technical excellence with strategic insight, global capabilities and long-term commitment. Ponchi brings a unique combination of industry expertise, customer focus and global perspective. Her decision to join 3PBIOVIAN is a strong endorsement of the company we are building and of the opportunity ahead of us. Her leadership will be instrumental in accelerating our commercial strategy, strengthening our customer relationships and further establishing 3PBIOVIAN as a leading global CDMO partner,” said Elena Erroba, Chief Commercial Officer at 3PBIOVIAN.
Ponchi’s appointment represents a significant step in 3PBIOVIAN’s evolution as a global CDMO. As the company continues to expand its international presence and capabilities, strengthening its commercial leadership with experienced industry executives will play a key role in accelerating growth and deepening partnerships with biopharmaceutical companies worldwide.
By bringing together deep scientific and manufacturing expertise, global capabilities and senior industry leadership, 3PBIOVIAN is reinforcing its position as a trusted partner for customers navigating increasingly complex development and manufacturing journeys and helping innovative therapies reach patients worldwide.
ABOUT 3PBIOVIAN
3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharmaceutical companies. Its service offering includes protein expression and production platforms based on microbial strains and mammalian cells, plasmid DNA, viral vectors including adenovirus and adeno-associated virus (AAV) for gene therapy, and cell therapy products. The company also provides fill-and-finish services for recombinant proteins and viral vectors.
3PBIOVIAN operates manufacturing facilities in Pamplona-Noáin, Spain, and Turku, Finland, supporting the diverse needs of its clients from preclinical and clinical supply through to large-scale commercial manufacturing of drug substance and drug product. www.3pbiovian.com
MEDIA CONTACTS
Edurne Gil
Head of Marketing and Communications
egil@3pbiovian.com +34 948 34 64 80